B-cell type acute leukaemia

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
CAR-T cell therapy 1 substance
Phase III: 1 Phase I (First in Human): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Novartis Pharma Services AG Commercial
    AUTOLOGOUS T-CELLS ENCODING A CHIMERIC ANTIGEN RECEPTOR TARGETING HUMAN B CELL MATURATION ANTIGEN; RAPCABTAGENE AUTOLEUCEL
    2023-508128-37-00 12 countries 2017 n=222
    Recruiting

Phase I (First in Human)

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR-443579
    2023-508357-58-00 2 countries 2022 n=57
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma Services AG Commercial 1 Phase III 1
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase I (First in Human) 0
New trials by year
2022
1
← All indication landscapes